BCL2alpha-MJK2243 Citations (1)

Originally described in: The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.
Goodis CC, Eberly C, Chan AM, Kim M, Lowe BD, Civin CI, Fletcher S Eur J Med Chem. 2024 Dec 22;285:117190. doi: 10.1016/j.ejmech.2024.117190. PubMed Journal

---

Articles Citing BCL2alpha-MJK2243

Articles
Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors. Chan AM, Eberly C, Drennen B, Goodis CC, Wuyts Z, Civin CI, Fletcher S. Drug Dev Res. 2025 May;86(3):e70084. doi: 10.1002/ddr.70084. PubMed

If you have published an article using this material, please email us at to have your article added to this page.